Healthcare AI Vendor Transparency: How to Turn Algorithm Facts Into a Local Decision

Author: Eunoia Consulting Co. | Published: October 21, 2026

Learn how healthcare leaders can turn AI vendor documents, model information and product claims into a local decision record that identifies intended use, data, evidence, human review, limitations, lifecycle change and accountable implementation conditions.

Healthcare AI buyers are often given a great deal of information: a model card, a product sheet, a security overview, a validation summary, an integration diagram, a contract schedule or a presentation that explains responsible AI. The problem is not a lack of documents. The problem is deciding which facts matter for a specific workflow, which claims are supported by evidence and which questions remain open.

Vendor transparency becomes useful when it helps an organisation make a local decision. It should reveal what the tool is intended to do, the conditions under which it was evaluated, what data and users are involved, how the output can influence work, where human review sits and what changes need to be revisited. A transparency document is not a substitute for implementation testing, clinical oversight, privacy review or accountable governance.

This guide is a practical operating framework. It does not provide legal, medical, privacy, security or regulatory advice.

Separate the vendor’s facts from the organisation’s decision

A vendor may accurately describe a feature without proving that the feature is appropriate for every customer. The first step is to distinguish two questions:

• What does the vendor state about the product, model, feature, data, performance and limitations?
• What does the healthcare organisation decide about the proposed local use?

These are connected but not identical. A performance study may apply to a different setting, population, data source, implementation configuration or human-review arrangement. A security document may be relevant but not answer who will use the output or how a failed integration will be reconciled. A transparency review should make those gaps visible.

Build a simple evidence record that includes the claim, source document, version, date, scope, limitation, local relevance, accountable reviewer, open action and decision status. The point is not to create a longer spreadsheet. It is to prevent confident language from becoming an untested local conclusion.

Ask for an intended-use statement you can test

The most valuable transparency question is often the simplest: what is the feature intended to do, for whom and in which workflow?

A precise answer should identify the user, input, output, use setting, decision role and limits. It should explain whether the output is an administrative draft, a recommendation, a prioritisation signal, a decision-support intervention or another type of assistance. It should also state what the tool is not intended to do.

If a feature is described only as “AI for healthcare operations,” the organisation still needs to know whether it drafts content, classifies information, routes work, predicts a risk, suggests an action or automates a decision. Each use has different human-review, validation, monitoring and escalation needs.

The National Institute of Standards and Technology’s AI Risk Management Framework is voluntary guidance intended to help organisations incorporate trustworthiness considerations into AI design, development, use and evaluation. Its approach is useful here because it begins with the context of the system and its use rather than treating technical documentation as the whole decision. Read the NIST AI RMF.

Read algorithm information as a decision packet

For each AI-enabled feature, organise the available material into six areas.

1. Purpose and boundaries

Record the stated intended use, intended users, output type, target setting and prohibited or unsupported uses. Ask whether the feature can be configured differently across sites and what controls prevent unapproved expansion of use.

2. Inputs, data and interfaces

Map the data or records entering the feature, where they come from, how often they update, what transformations occur and what happens if information is missing or late. Include integrations, access roles, retention statements, logs, subprocessors and any information the vendor says is used to improve the product.

A diagram can help, but a diagram alone is not enough. Ask which system is the source of truth, who owns data-quality exceptions and how the team detects a failed or incomplete transfer.

3. Evidence and evaluation context

Do not copy a headline performance number into a decision record without context. Identify the product or model version, task, data source, population, setting, evaluation method, outcomes, limitations and date of the evidence. Note whether the local organisation expects the same conditions.

An evidence source can be useful without being fully transferable. Record what it demonstrates and what it does not demonstrate locally. This distinction reduces the risk of treating a vendor study as proof of local performance.

4. Human factors and workflow design

Transparency should describe the human role as well as the system role. Who sees the output? What source information can they consult? Can they edit, ignore, override, escalate or pause the feature? What training is needed? Is the output visible in a way that could create automation bias or unclear responsibility?

A tool can be technically transparent and still fail if its users cannot understand how to handle an exception. Ask for workflow materials, not only technical descriptions.

5. Change and lifecycle practices

Version changes, new data sources, changed integrations, expanded user groups and new features can all alter the original decision. Ask how the vendor communicates changes, what documentation accompanies a release, what customers can test, how known limitations are shared and what rollback or disablement path is available.

6. Monitoring and feedback

Find out how the organisation can identify issues after launch. This may include audit information, usage data, support routes, exception logs, feedback channels and release notices. The healthcare organisation still needs its own monitoring and decision process. The vendor’s support channel is not the same as the organisation’s accountable oversight process.

Use HTI-1 as a focused transparency reference

The ASTP/ONC HTI-1 Final Rule establishes algorithm-transparency requirements for AI and other predictive algorithms that are part of certified health IT. It is a defined Health IT Certification Program context, not a general approval framework for every healthcare AI product.

Even so, the rule is useful to leaders because it highlights a practical expectation: clinical users need a consistent baseline of information about the algorithms they use to support decision making and to assess fairness, appropriateness, validity, effectiveness and safety. Read the HTI-1 Final Rule overview.

When a feature is within that context, identify the transparency information available to users and how the organisation will review it. When it is not, use the same discipline without claiming that the regulation applies. The question is still: do the people making a local decision have enough reliable information to understand the proposed use, evidence, limitations and operating conditions?

Ask questions that produce evidence, not sales language

Replace broad questions such as “Is the AI safe?” with questions that invite documentation and testable answers.

• Which product, feature and configuration version is this information about?
• What task, user, setting and decision role were evaluated?
• What data conditions or exclusions matter to the result?
• What known limitations, error patterns or unsupported uses are documented?
• What local implementation dependencies are assumed?
• Which user can override, correct or escalate an output?
• What happens when an input, interface or service becomes unavailable?
• What customer-visible information accompanies a material release?
• Which claims need a local workflow test before use?
• Who owns the decision if the evidence remains incomplete?

This question set helps procurement, clinical, operations, privacy, security and technical reviewers work from the same facts. It also reduces the burden on one person to interpret every document alone.

Document the decision and its conditions

A credible transparency review should end in more than a document folder. Record whether the organisation will proceed, proceed with conditions, defer for more information or decline the use case.

For a conditional decision, list the condition, accountable owner, evidence required, due date and consequence if it is not resolved. Conditions may include a local test, user training, interface reconciliation, contract review, access control, monitoring plan, escalation path or change-notification commitment.

A condition is not a failure. It is an honest statement of what must be true before the organisation becomes dependent on the feature.

For a fuller approach to linking claims and artefacts to owners, see Eunoia’s healthcare AI procurement evidence register. For post-launch releases and re-review triggers, use the companion healthcare AI vendor change-control guide.

Keep transparency connected to governance

Transparency is only valuable when it reaches the people who need it. A healthcare organisation may need different reviewers for clinical appropriateness, workflow design, privacy, security, contract obligations, financial impact and technical implementation. The purpose of a governance process is not to turn every purchase into a committee delay. It is to clarify which decision needs which perspective and where unresolved questions go next.

Eunoia Consulting Co. helps healthcare organisations translate vendor claims into testable questions, accountable decisions and operational conditions for AI adoption. Explore AI governance advisory or contact our team to discuss a focused vendor-transparency review for a proposed workflow.

Sources

• National Institute of Standards and Technology: AI Risk Management Framework
• ASTP/ONC: HTI-1 Final Rule